Vor Biopharma Inc. VOR
20.12 USD +0.26 (+1.31%)
At closeNov 4, 2026, 4:57 PM EST
20.34 +0.22 +1.09%
After hours · Nov 4, 4:57 PM ET
19.49 Day range 20.70
6.50 52-week range 26.00
- YTD
- +53.82%
- 1 year
- -2.14%
- Market cap
- 1.24B
- EPS (ttm)
- 304.49
- Shares out
- 61.43M
- P/E ratio
- 0.07
- Forward P/E
- -5.69
- YTD return
- +53.82%
- 1-year return
- -2.14%
- Volume
- 415.42K
- Avg volume
- 947.85K
- Open
- 20.63
- Previous close
- 19.86
- Day's range
- 19.49 – 20.70
- 52-week range
- 6.50 – 26.00
- Beta
- 1.83
- Analysts
- Strong Buy
- Price target
- 39.00 (+93.8%)
- Earnings date
- Mar 25, 2027
5D +0.15 (+0.77%)
Key statistics
- Enterprise value
- 741.34M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -46.94M
- Total cash
- 481.55M
- Total debt
- 2.81M
- Return on equity
- 0.00%
- Short % of float
- 14.17%
- 50-day average
- 20.61
- 200-day average
- 17.38
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 39.00 +93.8% upside
Now 20.12
- Target (low)
- 27.00
- Target (mean)
- 39.00
- Target (high)
- 50.00
Ratings (0m) 10 9 buy · 1 hold · 0 sell
- Strong buy1
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 25, 2027
Expected Mar 25, 2027. Consensus EPS estimate -0.81333.
Financials — quick view
VOR Revenue — quarterly 0
VOR Net income — quarterly -86.73M
VOR EPS — quarterly -1.45
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 25, 2027 | Mar 30, 2027 | -0.96181 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | -1.08 | -1.45 | -0.37 | -34.73% |
| Aug 11, 2026 | Jun 30, 2026 | -0.69 | -1.16 | -0.47 | -68.12% |
| May 13, 2026 | Mar 31, 2026 | -0.75 | -0.73 | +0.02 | +2.67% |
| Mar 30, 2026 | Dec 31, 2025 | -1.14 | 44.50 | +45.64 | +4,003.51% |
| Nov 13, 2025 | Sep 30, 2025 | -3.06 | -121.63 | -118.57 | -3,874.84% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | William Blair | init | — | Outperform |
| Aug 12, 2026 | Wedbush | main | Neutral | Neutral |
| May 18, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2026 | Wedbush | main | Neutral | Neutral |
| Apr 15, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 31, 2026 | Wedbush | main | Neutral | Neutral |
About Vor Biopharma Inc.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vorbio.com
News
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study 
Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropathy; TELIGAN Met Stage B Primary Endpoint 
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy 
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 
Vor Biopharma (NASDAQ:VOR) Shares Up 5.3% – What’s Next? 
Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 Weeks 
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis 
Vor Biopharma: A Funded Replication Story With Franchise Potential
Your note
Sign in to keep a note on VOR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANG ROBERT M.D. | Chief Executive Officer | Stock Award(Grant) | Feb 2, 2025 | 921,739 |
| ATTAR EYAL C | Officer | Sale | Feb 12, 2025 | 126,625 |
| CHAKRABORTY TIRTHA | Officer | Stock Award(Grant) | Feb 2, 2025 | 221,272 |
| CHOI HAN WOOK | Chief Financial Officer | Stock Award(Grant) | Feb 2, 2025 | 52,500 |
| MAHATME SANDESH | Chief Financial Officer | Stock Award(Grant) | Jul 8, 2025 | 13,882,800 |
| RA CAPITAL HEALTHCARE FUND,L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 23, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 9.23% | 5,673,078 | 114.14M | Jun 29, 2026 |
| FMR, LLC | 8.03% | 4,932,149 | 99.23M | Jun 29, 2026 |
| FCPM III Services B.V. | 6.70% | 4,117,354 | 82.84M | Jun 29, 2026 |
| Blackrock Inc. | 5.65% | 3,468,107 | 69.78M | Jun 29, 2026 |
| Venrock Adviser, LLC | 4.95% | 3,041,719 | 61.20M | Jun 29, 2026 |
| State Street Corporation | 4.26% | 2,616,336 | 52.64M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.52% | 1,550,885 | 31.20M | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2.28% | 1,399,605 | 28.16M | Aug 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.07% | 1,270,144 | 25.56M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.78% | 1,091,626 | 21.96M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.62% | 996,334 | 20.05M | Sep 29, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 1.23% | 758,112 | 15.25M | Aug 30, 2026 |